Owkin, AstraZeneca Expand AI Partnership for Drug Development

Owkin has entered into a new multi-year agreement with AstraZeneca to develop specialized artificial intelligence agents designed to support biopharmaceutical decision-making and competitive intelligence across drug discovery and development operations.

The collaboration centers around a three-year licensing agreement for K Pro, Owkin’s proprietary AI Scientist platform developed for biopharma applications. Under the agreement, Owkin will oversee the full development of AI-powered agents that will operate within AstraZeneca’s existing information technology systems and internal decision-making workflows.

According to the companies, the AI agents are intended to help AstraZeneca teams process complex competitive intelligence questions by providing faster access to data-driven insights while reducing the need for extensive manual analysis. The technology is also designed to function within established governance, enterprise security, and compliance standards used by the pharmaceutical company.

Owkin describes K Pro as a platform that combines multimodal data analysis with agentic artificial intelligence systems tailored for biological and pharmaceutical research. The company has positioned itself as a leader in the emerging field of “Biological Artificial Superintelligence,” which aims to apply advanced AI systems to better understand human biology and accelerate drug discovery.

Thomas Clozel, co-founder and Chief Executive Officer of Owkin, said the pharmaceutical industry is increasingly moving toward agentic AI systems capable of supporting complex scientific and strategic decision-making. He stated that Owkin’s infrastructure, biological data capabilities, and AI expertise allow the company to develop advanced agents that can help pharmaceutical partners rapidly interpret competitive intelligence and support executive-level decisions.

The new collaboration expands an existing relationship between the two companies. Owkin and AstraZeneca previously worked together on the development of an AI-based germline BRCA pre-screening solution for breast cancer patients. Results from that project were presented at the European Society for Medical Oncology (ESMO) conference, where the BRCAura research-use-only solution reportedly identified approximately 40% of patients unlikely to carry germline BRCA mutations while maintaining high sensitivity levels of 93%.

That diagnostic-focused program is now being continued by Waiv, a recently launched spin-out from Owkin’s diagnostics division. Meanwhile, Owkin said it will continue concentrating on its broader mission of developing AI systems capable of understanding complex biological processes and improving pharmaceutical research efficiency.

The agreement reflects growing interest across the healthcare industry in the use of generative and agentic AI technologies to improve research productivity, streamline clinical development, and accelerate strategic decision-making. Pharmaceutical companies are increasingly investing in AI platforms that can analyze vast amounts of biomedical, clinical, and market data to identify new treatment opportunities and reduce development timelines.

Financial terms of the agreement between Owkin and AstraZeneca were not disclosed.